Rapport Therapeutics Q2 net loss $18.1M; cash $336.1M; IPO raised $174.4M gross

Rapport Therapeutics, Inc.

2024-Q2 EPS reported -$6.42

Net loss $18.1M vs $6.4M YoY; R&D expense $15.7M vs $4.7M YoY.
Cash, cash equivalents and short-term investments $336.1M, expected to fund operations through end of 2026.
IPO with concurrent private placement raised $174.4M gross ($157.6M net).
Phase 2a trial of RAP-219 in focal epilepsy on track for Q3 2024 initiation; topline data mid-2025.
Board member Terry-Ann Burrell to transition off board after Form 10-Q filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.